In Europe, BIAL has a production and R&D unit in Portugal and affiliates in Spain, Germany, United Kingdom, Italy and Switzerland.
In 1998, the group acquired a Spanish pharmaceutical company, becoming BIAL Spain. Currently, BIAL Spain markets a range of products focused on neurology, internal medicine, cardiology and women’s health.
The company has opened affiliates in Germany, the United Kingdom, Italy and in Switzerland where its main scope of operation is neurosciences. BIAL also owns Novipharma
, that is located in Switzerland.
In the US, BIAL has established BIAL Biotech Investments Inc. (BIAL Biotech).
BIAL Biotech is a center of excellence for the development of genetically-defined Parkinson’s disease therapeutics located in the heart of the Boston biotech cluster.
BIAL Biotech is a wholly owned subsidiary of BIAL.
We collaborate with renowned partners in order to deliver our medicines to everyone. This is the case of some European countries, USA, Japan, China and South Korea.
We believe that delivering innovative medicines worldwide requires collaboration. Therefore, we have entered into licencing agreements with leading pharmaceutical companies. This broad network of partnerships has enabled us to share our innovative products in the neurosciences field in various countries.
BIAL has a branch in Panama since 2008, from which it operates in twelve countries in the region where it markets its products: Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Nicaragua, Panama and Venezuela.
BIAL markets a range of medicines covering different therapeutic fields in the region, namely in women’s health, maternal and central nervous system health.
BIAL has been present in Angola since the 1990s, first with export operations and, since 2008, through the creation of BIAL Angola.
BIAL Angola is one of the leading pharmaceutical companies in the country and has a wide range of products (over 40 medicinal products), from women’s and maternal health, to the treatment of infectious diseases, to neurological diseases.
French West Africa
BIAL products have been marketed its medicinal products in French-Speaking African countries since 1999, and the company has been present in the region through a subsidiary located in the Ivory Coast since 2013.
Through partnerships with local promotion agents, BIAL Francophone Africa operates in 18 countries in the region including Benin, Burkina Faso, Cameroon, Chad, Congo Brazzaville, Ivory Coast, Gabon, Guinea, Mali, Mauritania, Niger, Djibouti, Central African Republic, Madagascar, Mauritius, Cape Verde, Senegal and Togo.
The BIAL portfolio highlights therapeutic solutions of the central nervous system, maternal health and women’s health as well as solutions for respiratory diseases.
In Mozambique, BIAL owns Medimport. Established in 1996, the company is engaged in the import and distribution of pharmaceutical specialties, representing several pharmaceutical companies, with which it has licencing agreements for Mozambique.
Medimport is a leading company in the outpatient market, and since 2013 it has also had a strong position in the hospital/public procurement market.